Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 854 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical... May 27, 2025 Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma December 18, 2024 Woman Creates Non-Toxic Nail Polish Brand After Her Mom’s Breast Cancer... November 20, 2020 Nivolumab Plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage... October 30, 2024 Load more HOT NEWS ASCO Annual Meeting 2023: Improving Patients’ Lives Through Collaboration, Research, and... Alex Trebek Gets Choked Up Seeing Contestant’s Heartfelt ‘Guess’ As Final... Efficacy and Safety of Trastuzumab Deruxtecan in Exploratory Cohorts of Patients... Hopes for the future of cancer research – a video from...
